Drug class
Antiretroviral - Capsid Inhibitors
Antiretroviral capsid inhibitors are a distinct therapeutic drug class designed to treat human immunodeficiency virus type 1 (HIV-1) infection. Read more about Antiretroviral - Capsid Inhibitors
5 drugs in this class 1 manufacturers
Drugs in Antiretroviral - Capsid Inhibitors
SUNLENCA (lenacapavir sodium)
YEZTUGO (lenacapavir sodium)
BIXLENVO (bictegravir sodium/lenacapavir sodium)
BIXLENVO-SUNLENCA (bictegravir sodium/lenacapavir sodium)
Antiretroviral capsid inhibitors are a distinct therapeutic drug class designed to treat human immunodeficiency virus type 1 (HIV-1) infection.
These agents directly bind to the viral capsid protein, selectively disrupting multiple essential stages of the viral replication cycle, including nuclear import of viral genetic material, core disassembly, and mature capsid core formation.
Clinically, capsid inhibitors—exemplified by lenacapavir—are primarily utilized in combination with an optimized background regimen for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who have limited remaining treatment options due to resistance, intolerance, or virologic failure.
-
fda.gov
Antiretroviral capsid inhibitors are a distinct therapeutic drug class designed to treat human immunodeficiency virus type 1 (HIV-1) infection
-
fda.gov
Antiretroviral capsid inhibitors are a distinct therapeutic drug class designed to treat human immunodeficiency virus type 1 (HIV-1) infection
-
uspharmacist.com
Antiretroviral capsid inhibitors are a distinct therapeutic drug class designed to treat human immunodeficiency virus type 1 (HIV-1) infection These agents directly bind to the viral capsid protein, selectively disrupting multiple essential stages of the viral replication cycle, including nuclear import of viral genetic material, core disassembly, and mature capsid core formation Clinically, capsid inhibitors—exemplified by lenacapavir—are primarily utilized in combination with an optimized back...
-
nih.gov
These agents directly bind to the viral capsid protein, selectively disrupting multiple essential stages of the viral replication cycle, including nuclear import of viral genetic material, core disassembly, and mature capsid core formation
-
fda.gov
Clinically, capsid inhibitors—exemplified by lenacapavir—are primarily utilized in combination with an optimized background regimen for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who have limited remaining treatment options due to resistance, intolerance, or virologic failure
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.